GPR120 agonists improved insulin resistance in long-term administration (≥8 weeks) (Oliveira et al., 2015; Jia and Liu, 2022), but did not ameliorate postprandial hyperglycemia by single oral administration 30 min before glucose load in mice (Li et al., 2017). Here, FFAR4 is linked to Insulin resistance.